INT100582

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 1.69
Pain Relevance 1.33

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (Stil)
Anatomy Link Frequency
thymocytes 1
Stil (Mus musculus)
Pain Link Frequency Relevance Heat
alcohol 7 99.82 Very High Very High Very High
Morphine 2 96.80 Very High Very High Very High
cocaine 2 96.32 Very High Very High Very High
rheumatoid arthritis 58 95.52 Very High Very High Very High
Inflammation 12 95.20 Very High Very High Very High
cytokine 4 93.72 High High
methotrexate 36 90.68 High High
abatacept 1 87.16 High High
anakinra 1 84.92 Quite High
Etanercept 1 83.36 Quite High
Disease Link Frequency Relevance Heat
Rheumatic Diseases 1 99.64 Very High Very High Very High
Autoimmune Disease 9 98.12 Very High Very High Very High
Rheumatoid Arthritis 59 95.52 Very High Very High Very High
INFLAMMATION 15 95.20 Very High Very High Very High
Disease 13 84.36 Quite High
Cancer 3 84.16 Quite High
Necrosis 2 82.12 Quite High
Targeted Disruption 2 80.76 Quite High
Synovitis 2 63.32 Quite High
Juvenile Chronic Polyarthritis 1 38.56 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Alcohol did not increase sIL-2R release in Oncomice as it did in FVB mice thymocytes.
Positive_regulation (increase) of sIL in thymocytes associated with alcohol
1) Confidence 0.49 Published 2001 Journal Immunopharmacol Immunotoxicol Section Abstract Doc Link 11792018 Disease Relevance 0.24 Pain Relevance 0.48
The levels of IL-6 and its soluble receptor (sIL-6ra) are elevated in many rheumatic diseases.7,8 and the overproduction of IL-6 is thought to play a role in the pathogenesis of RA.9 Encouraging data from several clinical trials have led to the approval of tocilizumab in Europe in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe active RA who has inadequate response from previous treatment with one or more disease-modifying antirheumatic drugs (DMARDs) or tumor necrosis factor inhibitors (TNF).
Positive_regulation (elevated) of sIL associated with necrosis, cancer, rheumatoid arthritis, disease, methotrexate and rheumatic diseases
2) Confidence 0.45 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857613 Disease Relevance 1.45 Pain Relevance 0.85

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox